Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974909 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8974912 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8975062 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8975043 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8974671 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8975210 | 1.00 | GRM2 (0.60) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8974935 | 0.89 | GRM2 (0.58) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8975039 | 0.87 | GRM2 (0.49) | GRM2MAPK1L3MBTL1 | |
| SCHEMBL8974756 | 0.86 | GRM2 (0.57) | GRM2MAPK1L3MBTL1FKBP1A | |
| SCHEMBL8857400 | 0.85 | GRM2 (0.58) | GRM2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5578620-A | TREATMENT OF DIABETES AND HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1996-11-26 | — | — | US | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |